USC researchers have engineered CAR T cells to deliver a dual protein therapy that targets solid tumours – offering hope for cancers previously resistant to treatment.
Chimeric antigen receptor (CAR) T-cell therapy, which uses a…
USC researchers have engineered CAR T cells to deliver a dual protein therapy that targets solid tumours – offering hope for cancers previously resistant to treatment.
Chimeric antigen receptor (CAR) T-cell therapy, which uses a…